ROBERT ILOWITE
Physician in Millstone, NJ
License number
Pennsylvania OS008502L
Category
Osteopathic Medicine
Type
Osteopathic Physician and Surgeon
Address
Address
2
Millstone, NJ 08844
Pennsylvania
Pennsylvania
Organization information
See more information about ROBERT ILOWITE at bizstanding.comDermatology Center - Robert Ilowite Do
505 Omni Dr, Hillsborough, NJ 08844
Categories:
Dermatology Physicians & Surgeons, Osteopathic Physicians & Surgeons, Physicians & Surgeons
Phone:
(908) 359-6685 (Phone)
Specialties:
Dermatology
Products:
Spider Vein Treatments
Payment options:
All Major Cards Accepted, American Express, Diner's Club, ...
Additional:
Medicare & Medigap
Professional information
Dr. Robert K Ilowite, Hillsborough NJ - DO (Doctor of Osteopathic Medicine)
Specialties:
Dermatology
Address:
Dermatology Center
505 Omni Dr, Hillsborough 08844
(908) 359-6685 (Phone)
505 Omni Dr, Hillsborough 08844
(908) 359-6685 (Phone)
Certifications:
Dermatology
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Dermatology Center
505 Omni Dr, Hillsborough 08844
Hunterdon Medical Center
2100 Wescott Dr, Flemington 08822
505 Omni Dr, Hillsborough 08844
Hunterdon Medical Center
2100 Wescott Dr, Flemington 08822
Education:
Medical School
Philadelphia College of Osteopathic Medicine
Graduated: 1992
Philadelphia College of Osteopathic Medicine
Graduated: 1992
Methods Of Treating Subclinical Sun Damage
US Patent:
2011030, Dec 8, 2011
Filed:
Jan 18, 2011
Appl. No.:
13/008539
Inventors:
Robert K. Ilowite - Hillsborough NJ, US
International Classification:
A61K 31/7072, A61P 17/02, A61K 31/513
US Classification:
514 51, 514274, 514 50
Abstract:
Provided are methods of treating subclinical sun damage and of inducing a chemocytotoxic response in skin. Methods of treating subclinical sun damage include the steps of: topically administering to skin of a patient a composition comprising a chemocytotoxic agent in an amount effective to induce erythema, scaling, crusting, or combinations thereof and resolve at least a portion of the subclinical sun damage, where the skin has a condition of no clinical sign of sun damage and the patient was not previously treated for actinic keratosis or nonmelanoma skin cancer. The chemocytotoxic agent can comprise a fluorinated pyrimidine antimetabolite such as 5-fluorouracil (FU), 5-fluorouridine (FUR), 5-fluorouridine-5′-monophosphate (FUMP), 5-fluorodeoxyuridine (FUdR), 5-fluorodeoxyuridine-5′-monophosphate (FdUMP), or combinations thereof.